At a Glance
Quickcomparison
Dose Range
KPV (Alpha-MSH Fragment)
200 mcg–1500 mcg mcg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
Oral
Subcutaneous injection
Cycle Length
Ongoing/indefinite
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Anti-Inflammatory
Gut Health
Healing & Recovery
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C16H30N4O4
Molecular Weight
342.43 Da
Half-Life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS Number
67727-97-3
C62H98N16O22
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
starting
200 mcg
Lower end of the subcutaneous practice range for systemic anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH and acts on NF-kB signaling [3][6].
standard
300-500 mcg
Most commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
1000-1500 mcg
Oral route is used for gut-directed effects (e.g., IBD/ulcerative colitis models), taking advantage of PepT1 uptake; preclinical colitis studies support this application, doses are research practice [2][6].
0.01-0.1% cream or serum
Twice daily
7-14 days (acute) up to 4-8 weeks (chronic)
Applied as a 0.01-0.1% topical formulation to affected skin for localized inflammation (eczema, rosacea, post-procedure redness); penetration enhancers are often added. Research/practice use [6].
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Commonly used range for tissue and tendon recovery in research practice [1][3].
advanced
500 mcg
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Applications
Bestsuited for
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Injection Site Reaction
Mild GI Effects
Transient Skin Effects
Mild Immune Modulation
Peptide Stability Concerns
Uncommon
Theoretical Immunosuppression
Serious
Immune Tolerance Development
Injection site redness
Mild nausea
Dizziness
Headache
Fatigue
Hot/cold sensations
Allergic reaction
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
xNot approved for human clinical use
xUnknown interactions with immunosuppressive medications
xInsufficient safety data for pregnancy and lactation
xPotential melanocortin receptor effects in susceptible individuals
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose KPV (Alpha-MSH Fragment) if...
Inflammatory bowel disease research
Gut anti-inflammatory therapy development
Skin inflammation and wound healing
Cytokine-mediated inflammation studies
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health